Advancing Manufacture of Cell and Gene Therapies VI

Poster Presentations

November 21, 2018

Advances in cell processing: New technologies for new therapies

1	BIO regulates the <i>ex vivo</i> expansion and function of hematopoietic stem cells by inhibiting GSK-3β Qihao Sun (East China University of Science and Technology, China)
2	Dynamic culture in shake flask improved ex vivo expansion of cytokine-induced killer cells by upregulating glucose consumption rate and utilization efficiency Weiwei Zhang (East China University of Science and Technology, China)
3	Single Use Disposable BioSettler removes the dead cells and cell debris selectively to increase the viability percentage of mammalian cells (e.g., CAR-T) during expansion Dhinakar Kompala (Sudhin Biopharma Company, USA)
4	Use of the nanobridge system for the rapid production of pluipotent stem cells and neural progenitor cells Peter P. Gray (AIBN, University of Queensland, Australia)
5	Challenges and opportunities for closed processing in autologous CAR-T manufacturing John Wesner (Juno Therapeutics, USA)
6	Scalable generation of cerebellar neurons from pluripotent stem cells Carlos Rodrigues (IST Lisbon, Portugal)
7	Human pluripotent stem cell expansion in vertical-wheel bioreactors Carlos Rodrigues (IST Lisbon, Portugal)
8	Pancreas organoids for type I diabetes mellitus - Is it feasible as a cell therapy? Bart van Dijk (Lonza, Netherlands)
9	Defined osmolyte-based cryopreservation strategy for efficient processing of human iPS cells Rui Li (University of Minnesota, USA)
10	Establishment and evaluation of the suspension culture system for umbilical cord-derived mesenchymal stromal cells Hikari Hasegawa (ROHTO Pharmaceutical Co., Japan)
11	Scalable manufacturing of human mesenchymal stem/stromal cells and derived exosomes in the single-use, vertical-wheel bioreactor system using a human platelet lysate culture supplement Ana M. Fernandes-Platzgummer (IST Lisbon, Portugal)
12	Viable manufacture of cell therapies through the integration of multiple unit processes onto a counter-flow centrifugation device Alexander S. Klarer (Hitachi Chemical Advanced Therapeutic Solutions, USA)
13	A novel type of 2.5D microcarriers for culture in 3D platform and monitoring/observation in 2D platform EunAh Lee (Kyung Hee University, South Korea)

14	Process optimization and scale-up in the iCELLis® nano bioreactor system for production of an AAV2 viral vector using transient transfection Terése L. Joseph (Pall Biotech, USA)
15	Developing a novel microchannel emulsification device for diabetes cell therapy Christina Bitar (McGill University, Canada)
16	A scalable xeno-free microcarrier suspension bioreactor system for regenerative medicine biomanufacturing of hMSCs Josephine Lembong (RoosterBio Inc., USA)
17	"Smart" bioreactor culturing systems for cell therapy manufacturing Erika McAfee (Lonza, USA)
18	Cell therapy for bone defects using umbilical cord MSC-derived osteoblasts Hyun Sook Park (CEFO, South Korea)
19	Process development for increased MSC production in stirred tank bioreactors Kara Levine (MilliporeSigma, USA)
20	Further evaluation of a novel COP container system for the cryopreservation of adherent and suspension human cell types Alexander Lyness (West Pharmaceutical Services, Inc., USA)
21	Enabling stem cell based therapies: adaptable and scalable manufacturing of human pluripotent stem cells Inbar Friedrich Ben-Nun (Lonza, USA)
22	Maintaining CD4/CD8 ratio and Th1-CTL subsets of chimeric antigen receptor (CAR)-T cells in serum-free culture conditions Hsin-Lin Lu (Development Center for Biotechnology, Taiwan)
23	Scale-up study for ex-vivo expansion of allogeneic natural killer cells in stirred- tank bioreactor Juyoung Kim (GreenCross LabCell, South Korea)
24	A step closer to industrial scale manufacture of exosomes - Adaptation of clinical grade neural stem cells from 2D to 3D culture Nicola Goddard (University College London, UK)
25	In vitro high expansion of chimeric antigen receptor (CAR)-T cells in serum-free process conditions Wei-Kuang Chi (Development Center for Biotechnology, Taiwan)
26	Reducing variability in conditions for cell handling improves MSC yields Alicia D. Henn (BioSpherix, USA)
27	Impact of the dynamic culture system for 3D high cell density neural differentiation of hESC in electrospun PCL scaffolds Veronique Chotteau (KTH, Sweden)
28	Superior expansion of long-term hematopoietic stem cells using StemPro™ HSC medium kit Navjot Kaur (Thermo Fisher Scientific, USA)
29	An automated and closed system for patient specific CAR-T cell therapies Joseph W. O'Connor (Lonza, USA)

30	Stem cell bioprocessing: Culture challenges and future trends for regenerative medicine
	Marco Rito-Palomares (Tecnológico de Monterrey, Mexico)
31	Automated manufacturing for iPSC-derived retinal pigment epithelial cells Masahiro Kino-oka (Osaka University, Japan)
32	Translational requirements for manufactured dopaminergic neurons for the treatment of Parkinson's Disease James Kusena (Loughborough University, UK)
33	Isolation and expansion of human bone marrow-derived mesenchymal stem cells (hMSCs) directly on microcarriers in a stirred tank bioreactor Christopher J. Hewitt (Aston University, UK)
34	Mitigating the risks of adventitious agents in serum: Elimination or viral inactivation Kelly A. O'Neill (Celgene, USA)

Engineering challenges of in vivo gene therapy

35	LentiPro stable producer cells: delivering scalable and reliable lentiviral vector manufacturing
	Ana S. Coroadinha (IBET, Portugal)
36	Therapeutic Genome Editing for Charcot-marie-tooth Disease Type 1a Jae young Lee (ToolGen Inc., South Korea)
37	Outsourcing AAV Development and Manufacturing: Lessons from Multiple Campaigns
	Michael Xenelis (Voyager Therapeutics, USA)
38	Intracellular delivery of mRNA to human primary T cells with microfluidic vortex shedding
	Ryan Pawell (Indee Labs, USA)
39	Engineering characterization of a versatile vertical-wheel bioreactor for cell and
	gene therapy Matthew Croughan (Matthew S. Croughan Consulting Services, USA)
40	A novel scalable manufacturing platform for T-cell activation and expansion in
	adoptive T-cell therapy Jian Ling (Southwest Research Institute, USA)

Gene-modification of cells for therapy

41	A scalable and physiologically relevant system for human induced pluripotent stem cell expansion and differentiation Yuguo Lei (University of Nebraska-Lincoln, USA)
42	Towards an allogeneic therapy for neural regeneration
	Rachael Wood (Aston University, UK)
43	Engineering and manufacturing of probiotic E. Coli to treat metabolic disorder

	Eugene Antipov (Synlogic, USA)
44	CAR-T cell manufacturing: Fifteen years of academic driving Isabelle Riviere (Memorial Sloan Kettering Cancer Center, USA)
45	Development of a closed CAR-T manufacturing process Steven Loo-Yong-Kee (CCRM, Canada)
46	Leveraging bioprocess platform technology for the development of a robust, scalable, and economic manufacturing process of allogeneic CAR-T cell therapy products Frank Jing (AdicetBio, USA)
47	Characterization of CAR-T transduction parameters using a lentiviral vector Stefanie Shahan (Celgene, USA)
48	Platelet lysate boosts transgene levels and maintains undifferentiated T cell subtypes following lentiviral delivery to human primary T cells Christina Dann (Cook Regentec, USA)
49	New viral and non-viral platforms for T-cell engineering Xavier J. de Mollerat de Jeu (Thermo Fisher Scientific, USA)

Product characterization and analytics

50	Xeno-free expansion of late-adherent human olfactory mucosa cells: Towards an allogeneic therapy for neural regeneration Gerardo Santiago-Toledo (UCL, UK)
51	Decoding human cardiac stem cells regenerative potential in acute myocardial infarction Paula Marques Alves (IBET, Portugal)
52	Advancing the knowledge on immunomodulatory properties of human cardiac stem cells Paula Marques Alves (IBET, Portugal)
53	Cryopreservation critical process parameters: Impact on post-thaw recovery of cellular product Alireza Abazari (BioLife Solutions, USA)
54	Optimized media and workflow for the expansion of human pluripotent stem cells as aggregates in suspension cultures Eric Jervis (STEMCELL Technologies, Canada)
55	Refining iPSC-based 3D neural cell models and characterization tools to address brain microenvironment-related diseases Catarina Brito (IBET, Portugal)
56	Development of feeder-free PSC culture system enabling translational & clinical research David Kuninger (Thermo Fisher Scientific, USA)

Big data, analytics and control strategies

57	Metabolite-based model predictive control of cell growth Kathleen Van Beylen (KU Leuven, Belgium)
58	Streamlining cell therapy manufacturing: automated production and integrated data management Sébastien de Bournonville (KU Leuven, Belgium)
59	Unified electronic traceability and data storage system Matthew Marsh (Hitachi Chemical Advanced Therapeutic Solutions, USA)
60	Application of Quality by Design tools to upstream processing of platelet precursor cells to enable in vitro manufacture of blood products Elizabeth A. Cheeseman (Loughborough University, UK)
61	Dielectric spectroscopy monitoring of a bioreactor process for hiPSC expansion and differentiation Ines A. Isidro (IBET, Portugal)

Bioprocess modelling

62	Scaling up and industrialization the production and purification of viral vectors for therapeutic use: Challenges and progress Rachel Legmann (Pall, USA)
63	Updating lentiviral vector bioprocessing to accommodate biological and technological advances: Modelling the impact on workflow and suite designs Fernanda Masri (Sartorius Stedim, UK)
64	Continuous platform of virus production for gene therapy applications Seongkyu Yoon (UMass Lowell, USA)
65	Determining the role of lactate in induced pluripotent stem cell metabolism Daniel Odenwelder (Clemson University, USA)
66	Computational fluid dynamics (CFD) modeling of single-use, vertical-wheel bioreactors as a predictive scale-up tool for large scale stem cell culture Breanna Borys (University of Calgary, Canada)
67	A cost/quality analysis of primary human T-Cells in different expansion systems Marco C. Rotondi (UCL, UK)
68	High shear stress from a resonance phenomenon in Wave bioreactor revealed by computational fluid dynamics simulation Veronique Chotteau (KHT, Sweden)
69	Defining cell culture dynamics in response to growth factor provision for efficient optimization of cell based therapies Katie E. Glen (Loughborough University, UK)
70	Development of media production processes for CAR-T therapies Ryan C. Glussi (Celgene, USA)
71	Economics of lentiviral vector processes Ruxandra-Maria Comisel (UCL, UK)

Revolutionizing/Delivering the pipelines

72	CMC strategy for AAV gene therapies in the age of RMAT designation Rajiv Gangurde (Voyager Therapeutics, USA)
73	CAR T-cell therapies: The concept of a dynamic supply chain Maria Papathanasiou (Imperial College London, UK)
74	Advancing the robust manufacture of T-cell therapies through the application of stirred tank bioreactors Alexander S. Klarer (Hitachi Chemical Advanced Therapeutic Solutions, USA)
75	Automated filtration screening of lentiviral vectors with multiple envelope proteins Christopher Perry (UCL, UK)
76	Addressing the challenges of controlled, scalable, and affordable manufacture of Psc-derived allogeneic therapies Ricardo Baptista (Cell & Gene Therapy Catapult, UK)
77	Producer cell line engineering for large volume manufacturing of therapeutic AAV Jennifer Baerenwald (Biogen, USA)
78	Volume reduction, cell washing and affinity cell selection using multi- dimensional acoustic standing wave technology Bart Lipkens (FloDesign Sonics, USA)